Optibiotix Health Plc (LON:OPTI) CEO Stephen OHara today spoke about an article published in the telegraph. The article refers to a major Lancet study which backed the safety of statins where according to a group of medics underestimated the side-effects and said the study was ‘fundamentally flawed.’
Stephen OHara, OptiBiotix Health Plc CEO said: ‘This article reflects a growing concern over the side affects from statins. This can lead to high level of non compliance with some studies showing this to be a high as 40% after 2 years. Whilst many users will benefit from statins concerns over side affects and compliance means there is a growing gap between patient’s requirements and clinical practice, with the limitations of current approaches increasing interest in alternative treatment options. OptiBiotix products work by different mechanism of action to statins and will provide a range of cardiovascular products to reduce both LDL cholesterol and blood pressure, two factors known to increase cardiovascular risk. These products have the potential to provide a safe alternative or supplement to existing options to reduce cardiovascular risk’.
The article can be found here: http://www.telegraph.co.uk/news/2016/11/24/lancet-study-statins-fundamentally-flawed-critics-say/
Optibiotix Health Plc is a life sciences company developing a range of products to modify the human microbiome. The Company’s principal activity is research and development into microbiome modulators. It operates in UK segment. The Company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is operated by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology. Its Optiscreen is a screening and optimization technology platform designed to identify microbes within the human microbiome with metabolic pathways, which can interact with human physiological processes. Its OptiBiotic is a platform technology, which generates compounds and screens them for their ability to modulate the human microbiome and its microbial end products. Its platforms are applicable across a range of other human diseases.